NCT05493293 - Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

March 11, 2024

Study Completion Date

March 11, 2024

Conditions

Focal Onset SeizureFocal Onset Epilepsy

Interventions

DRUG

NBI-921352

Tablets for oral administration

Trial Locations (26)

1070

Neurocrine Clinical Site, Brussels

1145

Neurocrine Clinical Site, Budapest

3000

Neurocrine Clinical Site, Leuven

3004

Neurocrine Clinical Site, Melbourne

3065

Neurocrine Clinical Site, Fitzroy

3084

Neurocrine Clinical Site, Heidelberg

7623

Neurocrine Clinical Site, Pécs

8035

Neurocrine Clinical Site, Barcelona

9000

Neurocrine Clinical Site, Ghent

15006

Neurocrine Clinical Site, Prague

16000

Neurocrine Clinical Site, Prague

18600

Neurocrine Clinical Site, Prague

20133

Neurocrine Clinical Site, Milan

27100

Neurocrine Clinical Site, Pavia

28034

Neurocrine Clinical Site, Madrid

28040

Neurocrine Clinical Site, Madrid

31059

Neurocrine Clinical Site, Toulouse

35000

Neurocrine Clinical Site, Rennes

40139

Neurocrine Clinical Site, Bologna

40320

Neurocrine Clinical Site, Budapest

46026

Neurocrine Clinical Site, Valencia

51601

Neurocrine Clinical Site, Rychnov nad Kněžnou

59037

Neurocrine Clinical Site, Lille

65691

Neurocrine Clinical Site, Brno

69677

Neurocrine Clinical Site, Bron

708 52

Neurocrine Clinical Site, Ostrava